Evidence map›Paper›PMID 35155225›Full record

ArticleFrontiers in oncology2022

An Insight on the Pathways Involved in Crizotinib and Sunitinib Induced Hepatotoxicity in HepG2 Cells and Animal Model.

Lin Guo, Tingli Tang, Dongmei Fang, Hui Gong, Bikui Zhang, Yueyin Zhou, Leiyi Zhang, Miao Yan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. The Modulatory Effects of Statins, Vitamin E, and Moringa Oleifera Extract on CD3 Expression in Ribociclib-Induced Hepatotoxicity in Rats.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2025
    Article
  4. Article
  5. Sunitinib induced hepatotoxicity in L02 cellsFrontiers in pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lin GuoDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Tingli TangDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Dongmei FangDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Hui GongDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Bikui ZhangDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Yueyin ZhouOrthodontic Department of Xiangya Stomatology Hospital, Central South University, Changsha, China.
Leiyi ZhangDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Miao YanDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Second Xiangya Hospital of Central South University · CNCentral South University · CNStomatology Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Both crizotinib and sunitinib, novel orally-active multikinase inhibitors, exhibit antitumor activity and extend the survival of patients with a malignant tumor. However, some patients may suffer liver injury that can further limit the clinical use of these drugs, however the mechanisms underlying hepatotoxicity are still to be elucidated. Thus, our study was designed to use HepG2 cells

Indexed as

apoptosiscrizotinibhepatotoxicityKeap1/Nrf2liver mitochondrial injurysunitinib

Identifiers

PMID35155225
PMCPMC8832280
OpenAlexW4210271345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.